Long non‑coding RNA LINC00173 enhances cisplatin resistance in hepatocellular carcinoma via the microRNA‑641/RAB14 axis

Zhao, Guang-Liang; Zhang, Anhua; Sun, Shanwen; Ding, Yuanhua

doi:10.3892/ol.2021.12632

“…We found that LINC00173 expression is deregulated in all tumors, being underexpressed in 13 different tumor types (Log2FC > 1, p < 0.01, Supplementary Figure 10 ). Some of them have been reported previously ( 22 , 23 , 26 , 29 – 31 ), but underexpression and overexpression of LINC00173 were observed in six (DLBC, KICH, OV, THCA, UCEC, and UCS) and one (KIRC) non-reported tumor type, respectively ( Figure 6A ). After exploring the role of LINC00173 expression status in DFS and OS in the unreported tumors, we found that this lincRNA is related to the risk of relapse and death in all these cancer types (log2HR > 1, p < 0.05, Figures 6B , C ).…”

Section: Resultssupporting

confidence: 56%

Underexpression of LINC00173 in TCF3/PBX1-Positive Cases Is Associated With Poor Prognosis in Children With B-Cell Precursor Acute Lymphoblastic Leukemia

May-Hau

¹

,

Bárcenas-López

²

,

Núñez-Enríquez

³

et al. 2022

Front. Oncol.

2

0

View full text Add to dashboard Cite

BackgroundB-cell precursor acute lymphoblastic leukemia (BCP-ALL) is the most frequent pediatric cancer worldwide. Despite improvements in treatment regimens, approximately 20% of the cases cannot be cured, highlighting the necessity for identifying new biomarkers to improve the current clinical and molecular risk stratification schemes. We aimed to investigate whether LINC00173 is a biomarker in ALL and to explore its expression level in other human cancer types.MethodsA nested case–control study including Mexican children with BCP-ALL was conducted. LINC00173 expression was evaluated by qRT-PCR using hydrolysis probes. To validate our findings, RNA-seq expression data from BCP-ALL and normal tissues were retrieved from Therapeutically Applicable Research to Generate Effective Treatments (TARGET) and Genotype-Tissue Expression (GTEx) repositories, respectively. LINC00173 expression was also evaluated in solid tumors by downloading available data from The Cancer Genome Atlas (TCGA).ResultsA lower expression of LINC00173 in BCP-ALL cases compared to normal subjects was observed (p < 0.05). ALL patients who carry the TCF3/PBX1 fusion gene displayed lower expression of LINC00173 in contrast to other BCP-ALL molecular subtypes (p < 0.04). LINC00173 underexpression was associated with a high risk to relapse (HR = 1.946, 95% CI = 1.213–3.120) and die (HR = 2.073, 95% CI = 1.211–3.547). Patients with TCF3/PBX1 and underexpression of LINC00173 had the worst prognosis (DFS: HR = 12.24, 95% CI = 5.04–29.71; OS: HR = 11.19, 95% CI = 26–32). TCGA data analysis revealed that underexpression of LINC00173 is also associated with poor clinical outcomes in six new reported tumor types.ConclusionOur findings suggest that LINC00173 is a biomarker of poor prognosis in BCP-ALL and other types of cancer. We observed an association between the expression of LINC00173 and TCF3/PBX1 and the risk to relapse and die in BCP-ALL, which is worse in TCF3/PBX1-positive cases displaying underexpression of LINC00173. Experimental studies are needed to provide insight into the LINC00173 and TCF3/PBX relationship.

show abstract

“…Extensive studies have shown that lncRNAs served as vital functions in the drug resistance of HCC [ 5 , 6 ]. For instance, LINC01234 accelerated HCC cell line progression and chemoresistance by targeting the miR-31-5p/MAGEA3 axis [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Long non-coding RNA FGD5-AS1 contributes to cisplatin resistance in hepatocellular carcinoma via sponging microRNA-153-3p by upregulating Twinfilin Actin Binding Protein 1 (TWF1)

Yang

¹

,

Shi

²

,

Zhang

³

et al. 2021

View full text Add to dashboard Cite

Long non-coding RNA (lncRNA) FGD5 antisense RNA 1 (FGD5-AS1) was reported to exert critical roles in multiple cancers. The current work aimed to determine the role of FGD5-AS1 in cisplatin (DDP) resistance of hepatocellular carcinoma (HCC). The levels of FGD5-AS1, miR-153-3p, and twinfilin actin binding protein 1 (TWF1) were analyzed using RT-qPCR. CCK-8, colony formation, Transwell, and TUNEL assays were used to examine the IC 50 value of DDP, cell viability, invasion, and apoptosis. The interaction between miR-153-3p and TWF1 or FGD5-AS1 was determined by luciferase reporter and RIP assays. In our study, we found that FGD5-AS1 level was elevated in DDP-resistant HCC tissues and cell lines. FGD5-AS1 silencing improved the sensitivity of HCC cells to DDP. Moreover, FGD5-AS1 directly bound to miR-153-3p and FGD5-AS1 addition neutralized the inhibitory impacts of miR-153-3p supplementation on DDP resistance in the HCC cells. In addition, knockdown of TWF1 inhibited DDP resistance of HCC cells, which was reversed by miR-153-3p deletion. Lastly, FGD5-AS1 interference decreased TWF1 expression level, which was rescued by miR-153-3p inhibition. Our study exhibited that FGD5-AS1 promoted DDP resistance through modulating the miR-153-3p/TWF1 axis in HCC cells. This could be an effective treatment strategy for HCC patients.

show abstract

“…However, the role of AC015813.1 in KIRC remains unknown. As for LINC00173, its high expression promoted the progression of cervical cancer by targeting miR-3171 [ 50 ], hepatocellular carcinoma via the microRNA-641/RAB14 axis [ 51 ], triple-negative breast cancer [ 52 ], glioma through sponging miR-765 [ 53 ], colorectal cancer by regulating the miR-765/PLP2 axis [ 54 ], and lung squamous cell carcinoma by sponging miR-511-5p to regulate VEGFA expression [ 55 ]. In other studies, LINC00173 was reported to inhibit pancreatic cancer by repressing sphingosine kinase 1 protein expression [ 56 ].…”

Section: Discussionmentioning

confidence: 99%

Construction and Characterization of n6-Methyladenosine-Related lncRNA Prognostic Signature and Immune Cell Infiltration in Kidney Renal Clear Cell Carcinoma

Chen

¹

,

Huang

²

,

Hui

³

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

Background. Kidney renal clear cell carcinoma (KIRC) lacks effective prognostic biomarkers and the role and mechanism of N6-methyladenosine (m6A) modification of long noncoding RNAs (lncRNAs) in KIRC remain unclear. Methods. We extracted standard mRNA-sequencing and clinical data from the TCGA database. The prognostic risk model was obtained by Lasso regression and Cox regression. We randomly divided the samples into training and test sets, each taking half of the cases. Based on Lasso regression and Cox regression for training set, the prognostic risk signature was constructed; risk scores were calculated with the R package “glmnet.” Based on the median value of the prognostic risk score, risk scores were calculated for each patient and we divided all KIRC samples into high-risk and low-risk groups. Then, high- and low-risk subtypes were established and their prognosis, clinical features, and immune infiltration microenvironment were evaluated in test set and the entire sampled data set. The reliability of the prognostic model was confirmed by receiver operating characteristic curve analysis. Results. We found 28 prognostic m6A-related lncRNAs and established a m6A-related lncRNAs prognostic signature. Risk score = A C 015813.1 ∗ 0.0086 + E M X 2 O S ∗ − 0.0101 + L I N C 00173 ∗ 0.0309 + P W A R 5 ∗ − 0.0146 + S N H G 1 ∗ 0.0043 . The signature showed a better predictive ability than other clinical indicators, including tumor node metastasis classification (TNM), histological, and pathological stages. In the high-risk group, M0 macrophages, CD8+ T cells, and regulatory T cells had significantly higher scores. Contrarily, in the low-risk group, activated dendritic cells, M1 macrophages, mast resting cells, and monocytes had significantly higher scores. In the high-risk group, LSECtin was overexpressed. In the low-risk group, PD-L1 was overexpressed. Moreover, high-risk patients may benefit more from AZ628. Conclusions. In conclusion, prognosis prediction of patients with KIRC and new insights for immunotherapy are provided by the m6A-related lncRNA prognostic signature.

show abstract

Long non‑coding RNA LINC00173 enhances cisplatin resistance in hepatocellular carcinoma via the microRNA‑641/RAB14 axis

Cited by 13 publications

References 29 publications

Underexpression of LINC00173 in TCF3/PBX1-Positive Cases Is Associated With Poor Prognosis in Children With B-Cell Precursor Acute Lymphoblastic Leukemia

Underexpression of LINC00173 in TCF3/PBX1-Positive Cases Is Associated With Poor Prognosis in Children With B-Cell Precursor Acute Lymphoblastic Leukemia

Long non-coding RNA FGD5-AS1 contributes to cisplatin resistance in hepatocellular carcinoma via sponging microRNA-153-3p by upregulating Twinfilin Actin Binding Protein 1 (TWF1)

Construction and Characterization of n6-Methyladenosine-Related lncRNA Prognostic Signature and Immune Cell Infiltration in Kidney Renal Clear Cell Carcinoma

Contact Info

Product

Resources

About